34P Pembrolizumab (pembro) or placebo (pbo) + concurrent chemoradiotherapy (CCRT) for high-risk, locally advanced cervical cancer (LACC): Final analysis (FA) results from ENGOT-cx11/GOG-3047/KEYNOTE-A18 in participants (pts) enrolled in East Asia

In ENGOT-cx11/GOG-3047/KEYNOTE-A18 (NCT04221945), pembro (vs pbo) + CCRT significantly improved PFS and OS in the ITT population, with continued benefit at FA (HRs [95% CIs] of 0.72 [0.59–0.87] and 0.73 [0.57–0.94], respectively). In pts enrolled in East Asia, pembro + CCRT improved PFS at IA1 (median follow-up, 19.3 mo) and 2 (median follow-up, 31.2 mo), with HRs (95% CIs) of 0.55 (0.35-0.88) and 0.61 (0.40-0.93), respectively. We report FA results in pts enrolled in East Asia.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-07-01
DOI
https://doi.org/10.1016/j.esmoop.2026.108060
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

34P Pembrolizumab (pembro) or placebo (pbo) + concurrent chemoradiotherapy (CCRT) for high-risk, locally advanced cervical cancer (LACC): Final analysis (FA) results from ENGOT-cx11/GOG-3047/KEYNOTE-A18 in participants (pts) enrolled in East Asia

K. Hasegawa, T. Usami, Q. Zhou, A-A. Lertkhachonsuk et al.
ESMO Open
Endometrial and Cervical Cancer Treatments
article

34P Pembrolizumab (pembro) or placebo (pbo) + concurrent chemoradiotherapy (CCRT) for high-risk, locally advanced cervical cancer (LACC): Final analysis (FA) results from ENGOT-cx11/GOG-3047/KEYNOTE-A18 in participants (pts) enrolled in East Asia

K. Hasegawa, T. Usami, Q. Zhou, A-A. Lertkhachonsuk, Xi Zhang, T-C. Chang, C-L. Chang, K.U. Yamada, H P Zhu, S. Suzuki, W Zhao, G N Zhang, B-G. Kim, Y Xiang, J. Xu, J-Y. Lee, E. Tharavichitkul, C. Tekin, D. Lorusso
article en

Abstract

In ENGOT-cx11/GOG-3047/KEYNOTE-A18 (NCT04221945), pembro (vs pbo) + CCRT significantly improved PFS and OS in the ITT population, with continued benefit at FA (HRs [95% CIs] of 0.72 [0.59–0.87] and 0.73 [0.57–0.94], respectively). In pts enrolled in East Asia, pembro + CCRT improved PFS at IA1 (median follow-up, 19.3 mo) and 2 (median follow-up, 31.2 mo), with HRs (95% CIs) of 0.55 (0.35-0.88) and 0.61 (0.40-0.93), respectively. We report FA results in pts enrolled in East Asia.

ESMO OpenVol. 11
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Central South University (CN), University of Electronic Science and Technology of China (CN), Chongqing University (CN), Yonsei University (KR), Chinese Academy of Sciences (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Mahidol University (TH), Severance Hospital (KR), Peking Union Medical College Hospital (CN), Samsung Medical Center (KR), Agostino Gemelli University Polyclinic (IT), Mackay Memorial Hospital (TW), Zhejiang Cancer Hospital (CN), Ehime University Hospital (JP), Linkou Chang Gung Memorial Hospital (TW), Sichuan Cancer Hospital (CN), Anhui Provincial Hospital (CN), Aichi Cancer Center (JP), Ramathibodi Hospital (TH), Chongqing Cancer Hospital (CN), Xiangya Hospital Central South University (CN), Chiang Mai University (TH), Sungkyunkwan University (KR), Saitama Medical University (JP)
Good health and well-being
Openalex Percentile: Top 6%
Endometrial and Cervical Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.